Technology Review Sample Clauses

Technology Review. Within three months of the completion of the 2006 Technology Review referenced in Section V.A. of the SCGSE MOU, LAWA shall meet with the Coalition Representative for the purpose of reaching a mutually acceptable agreement on diesel emission reduction strategies for cargo loaders, Ground Power Units, air starts, and cargo tractors operated by Nonparticipating GSE Operators.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Technology Review. The Client may, at its own expense, conduct a review of technology standards each year, and Xxxxxx will provide reasonable co-operation to the Client in the conduct of that review. Any resulting changes required will be completed at Xxxxxx’x discretion.
Sample 1
Technology Review. The purpose of the technology review is to understand how exactly existing technologies have been formulated so that their strengths and limitations can be determined in anticipation of delivering a robust, harmonized model. For this a clear understanding of the vocabulary is needed, which in turn facilitates comparison of the existing technologies and hence the formulation of a harmonized model. The solution to the electronic representation of engineering materials data that this document proposes builds on prior work by ASTM E49, ISO TC 184/SC 4, NIST, and the JRC. It also takes into consideration complementary activities undertaken by CETIM (in the context of the Auto-gration project), the Kno.e.sis Center at Xxxxxx State University (in the context of the US MGI), and the CODATA/VAMAS Working Group on Nanomaterials12. Over the last three decades, a number of international efforts have investigated how to provide a viable electronic representation to describe engineering materials, suitable for database schema and electronic data exchange. The present work builds upon some of these efforts, which are describe briefly below, to take advantage of existing insights and knowledge for our solution. The complexity of modern materials is immense and contributes to the challenge of developing a successful solution. The earlier efforts often did not address some of this complexity, which is a major reason to develop a new solution.
Sample 1
Technology Review. On a continual basis Supervisory Staff will review available technology relating to winter control activities. This may consist of de-icing material, equipment, techniques, weather forecasting, and record keeping capabilities. Staff will make budget recommendations for suitable technological upgrades. Goals:  Continue to review available technology.  Staff recommends suitable technology for budget purposes.
Sample 1
Technology Review. TECHNOLOGY REVIEW OBJECTIVE To review existing and new technologies on an annual basis and recommend pilot studies on relevant and winter maintenance methodologies. ENVIRONMENTAL CONSIDERATION New techniques, procedures, and technologies may provide new methods for reducing salt entering the environment. CURRENT SITUATION 75% of equipment is presently using pre-wet, anti-icing and IRTs. GPS is being installed on 5 Combination units prior to the 2006/07 winter season GOAL • To keep up to date on future technologies, by working with OGRA, TAC, Ministry of the Environment, MTO, etc. • Continue with pre-wet and anti-icing techniques. • Phase in GPS units over next 3 years to include all combination units used in winter operations. RESPONSIBILITIES Management – To implement, monitor and report on trials and technical review. PERFORMANCE MEASURE • Report on new development(s) in Annual Report. REFERENCES Salt Management Plan
Sample 1
Technology Review. Methode shall be satisfied in its reasonable discretion that all Technology used by TST is adequately protected by Intellectual Property rights owned exclusively by TST.
Sample 1
Technology Review. 7.1. [*] Nothing in this Agreement shall be deemed (a) to prohibit Data Critical from developing and marketing any such enhanced or new products or (b) to grant Agilent any rights thereto hereunder.
Sample 1
AutoNDA by SimpleDocs
Technology Review. Available Upon Request per individual quote (billed separately).
Sample 1

Related to Technology Review

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!